Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol
Authors' conclusion
These findings provide unequivocal evidence that the extent of reduction of serum cholesterol achieved by a combination of therapeutic measures, including statins, ezetimibe, lipoprotein apheresis, and evolocumab, is a major determinant of survival in homozygous FH.
Study context
- Population
- Previously statin-naive homozygous familial hypercholesterolaemia (FH) patients treated with combined lipid-lowering measures, South Africa and UK, 1990–2014
- Participants
- 133 patients
- Exposure
- On-treatment serum cholesterol quartiles
- Outcome
- Any death (also CV death and MACE)
- Follow-up
- 25 years
Main finding
As reported in the abstract
Any death
Hazard ratio
11.5
P < 0.001
Quartile 4
Hazard ratio
3.6
P < 0.001
Quartiles 2 and 3
- Differences remained significant after adjustment for confounding factors
- P = 0.04
Observational data: associations, not effects.
Further findings
CV death and major adverse cardiovascular events (MACE)
- Significant differences between quartiles
Original publication
Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. Published 1 July 2017. doi:10.
Summarised from the published abstract; every number is checked against it